View Future GrowthSoftOx Solutions 과거 순이익 실적과거 기준 점검 0/6SoftOx Solutions은 연평균 19.2%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 8.8%의 비율로 증가했습니다. 매출은 연평균 4.3%의 비율로 증가했습니다.핵심 정보19.16%순이익 성장률30.59%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률12.39%매출 성장률4.31%자기자본이익률-47.11%순이익률-69.39%다음 순이익 업데이트10 Jun 2026최근 과거 실적 업데이트공시 • May 27+ 1 more updateSoftOx Solutions AS to Report Fiscal Year 2025 Results on May 27, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on May 27, 2026공시 • Dec 18+ 4 more updatesSoftOx Solutions AS to Report Fiscal Year 2025 Results on Jun 10, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on Jun 10, 2026공시 • Jan 25+ 5 more updatesSoftOx Solutions AS to Report Fiscal Year 2024 Final Results on Jun 18, 2025SoftOx Solutions AS announced that they will report fiscal year 2024 final results on Jun 18, 2025공시 • Dec 13+ 4 more updatesSoftOx Solutions AS to Report Q4, 2020 Results on Mar 31, 2021SoftOx Solutions AS announced that they will report Q4, 2020 results on Mar 31, 2021모든 업데이트 보기Recent updates공시 • 6hSoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments LimitedSoftOx Solutions AS has announced to issue 46 380 523 shares at an issue price of NOK 0.13 per share for gross proceeds of NOK 6,029,467.99 on June 9, 2026. The transaction includes returning investor participation from Long State Investments Limited.공시 • Jun 05SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical StudySoftOx Solutions AS announced that the first participant has been enrolled in the SIS-02 Phase 1 clinical study in Ireland. The enrollment follows the previously announced approval of the SIS-02 clinical trial application by Ireland’s Health Products Regulatory Authority (HPRA) and marks the formal initiation of the study. The SIS-02 Phase 1 study is designed to evaluate the safety, tolerability, and pulmonary exposure profile of SoftOx Inhalation Solution (“SIS”) following inhaled administration in healthy volunteers and supports the continued development of SIS for defence and biological countermeasure applications. The initiation of SIS-2 represents an important operational milestone for SoftOx and expands the Company’s clinical trial pipeline from one to two ongoing clinical studies. SIS-02 is separate from, and independent of, the Company’s SIS-03 study in chronic lung infections in patients, including cystic fibrosis. Together, the two SIS programs support SoftOx’s strategy to develop SIS as an inhaled anti-infective therapy with potential relevance in both civilian healthcare and defence-related biological preparedness. The SIS-02 program is formally conducted through SoftOx’s wholly owned subsidiary, SoftOx Defense Solutions AS, and is grant-funded through SoftOx’s participation in the COUNTERACT Consortium, which is funded by the European Defence Fund and includes universities, public research institutes, and companies across Europe. The program is also supported by the Norwegian Ministry of Defence. The SIS-02 study is intended to add to the clinical evidence base for SIS and support the planning of subsequent development activities. SoftOx will provide further updates on SIS-02 as the study progresses and when relevant data reviews have been completed. SoftOx Solutions AS is developing SIS, a novel inhaled anti-infective therapy for respiratory infections in the airways and lungs. Delivered by nebulizer, SIS is being developed to address bacterial, viral, and fungal pathogens through local delivery directly at the site of infection, without systemic exposure to the remainder of the human body. Its broad pathogen relevance positions SIS as a distinct therapeutic in respiratory infections.분석 기사 • Mar 28We Think SoftOx Solutions (OB:SOFTX) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Mar 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Revenue is less than US$5m (kr16m revenue, or US$1.6m). Market cap is less than US$100m (kr174.4m market cap, or US$18.1m).New Risk • Dec 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr219.9m market cap, or US$21.9m).공시 • Dec 19+ 5 more updatesSoftOx Solutions AS, Annual General Meeting, Jun 23, 2027SoftOx Solutions AS, Annual General Meeting, Jun 23, 2027.공시 • Sep 27SoftOx Solutions AS announced that it has received NOK 6 million in funding from Long State Investments LimitedOn September 26, 2025, SoftOx Solutions AS closed the transaction.공시 • Jun 30SoftOx Solutions AS Appoints Tore Duvold as New Board MemberSoftOx Solutions AS at its Annual General Meeting, announced the election of Dr. Tore Duvold as a new member of the Board of Directors. Dr. Duvold brings over 25 years of experience in the life science sector, including leadership roles in biotech, pharma, and public innovation funding. He currently serves as CEO of the Swedish diagnostics company Spermosens AB and has held senior positions at LEO Pharma, Aker Biopharma AS, Innovation Fund Denmark, Edvince AB, and Coegin Pharma. In addition, he has served on the board of Medicon Valley Alliance and been involved in several board roles.공시 • May 27+ 1 more updateSoftOx Solutions AS to Report Fiscal Year 2025 Results on May 27, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on May 27, 2026공시 • Dec 19SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026.공시 • Dec 18+ 4 more updatesSoftOx Solutions AS to Report Fiscal Year 2025 Results on Jun 10, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on Jun 10, 2026공시 • Sep 13SoftOx Solutions AS to Appeal Court Ruling in Consultant Bonus DisputeThe District Court of Ringerike, Asker, and Bærum has made its ruling in a dispute between SoftOx Solutions AS and a former consultant claiming to have a bonus claim for services rendered in 2022. The district court ruled in favor of the consultant and awarded the consultant approx. NOK 2.5 million plus interest, and NOK 484,000 in compensation including legal costs. The Company believes that the claim has no merits, and the ruling will be appealed.공시 • Sep 12SoftOx Solutions AS Elects Additional Board MembersSoftOx Solutions AS at its ExtraOrdinary General Meeting held on 12 September 2024, elected as additional board member: Christian Vinding Thomsen, Vice Chairman of the Board and Eskil Zapffe, board member with an election term until the annual general meeting in 2025.공시 • Jul 03+ 1 more updateSoftox Solutions as Announces CFO ChangesSoftOx Solutions AS announced that in this process the former CFO Harald Sætvedt has stepped down and will be replaced by CFO Ingrid Juven. Ingrid Juven has over 25+ years of consulting and management expertise within a variety of industries. Juven holds an MBA from BI Norwegian Business School.공시 • May 01SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million.SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million. Security Name: Shares Security Type: Common Stock Securities Offered: 13,345,951 Price\Range: NOK 0.2 Transaction Features: Rights OfferingNew Risk • Apr 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 47x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 47x increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$645k). Minor Risks Negative equity (-kr268k). Market cap is less than US$100m (kr156.1m market cap, or US$14.4m).New Risk • Apr 05New minor risk - Negative shareholders equityThe company has negative equity. Total equity: -kr268k This is considered a minor risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. It should be noted that some of the negative equity could be due to large buybacks of stock, which is not as much of a risk as a company with overwhelming debt, but likewise is not sustainable in the long-term. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$650k). Market cap is less than US$10m (kr4.29m market cap, or US$399.5k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).공시 • Mar 28SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million.SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million. Security Name: Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: NOK 0.2 Transaction Features: Rights OfferingNew Risk • Mar 27New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.0m (US$649k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$649k). Market cap is less than US$10m (kr8.84m market cap, or US$821.8k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).공시 • Jan 25+ 5 more updatesSoftOx Solutions AS to Report Fiscal Year 2024 Final Results on Jun 18, 2025SoftOx Solutions AS announced that they will report fiscal year 2024 final results on Jun 18, 2025New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (kr51.7m market cap, or US$4.79m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).Board Change • Mar 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Kari Myren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Dec 30+ 4 more updatesSoftOx Solutions AS, Annual General Meeting, Mar 28, 2024SoftOx Solutions AS, Annual General Meeting, Mar 28, 2024.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman Melvin Teigen was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Sep 01Is SoftOx Solutions (OB:SOFTX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...공시 • Mar 17Danish Medicines Agency Approves First-In-Human Clinical Study for SoftOx Solutions AS Wound Treatment Agent for Infections in Chronic Wounds, Biofilm EradicatorSoftOx Solutions AS announced that the Danish Medicines Agency (DKMA) has authorised the SBE-01 clinical trial on medicinal products. The authorisation is given pursuant to § 88(1) of the Danish Medicines Act.1. This is the first-in-man (phase I) study with lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. This approval represents an important milestone for SoftOx Solutions AS and is of crucial importance for the further development of an effective infection treatment of problematic wounds, where there is an unmet medical need. It is also an important step forward for the company's collaboration and funding partners, such as University of Copenhagen, Bispebjerg University Hospital, US Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) and The Research Council of Norway. The SBE-01 study will commence as soon as permission has also been granted by the relevant Scientific Ethical Committee. SBE-01: EudraCT no. 2021-000314-42.Is New 90 Day High Low • Feb 20New 90-day low: kr56.50The company is down 18% from its price of kr68.50 on 20 November 2020. The Norwegian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.분석 기사 • Feb 19How Many SoftOx Solutions AS (OB:SOFTX) Shares Have Insiders Sold, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...분석 기사 • Jan 15SoftOx Solutions (OB:SOFTX) Will Have To Spend Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. Indeed, SoftOx Solutions...공시 • Dec 23SoftOx Solutions AS Announces New Distribution AgreementSoftOx Solutions AS announced new distribution agreement. Distributor Bonaventura Scandza has signed an agreement with NorgesGruppen for the sale of SafeDes alcohol-free hand disinfectant. From February, some of the country's grocery chains will start selling SoftOx SafeDes hand disinfectant under the brand name «Aeris». The agreement with NorgesGruppen includes Meny, Spar, and Bunnpris stores, where 39 Meny stores will include the products in a fixed listing, while partner Bonaventura Scandza will be allowed to sell products to all the other stores locally. Meny has a total of 200 stores, Spar has 295, and Bunnpris has 250. As a result of increased focus on infection prevention and control among consumers, Bonaventura Scandza in collaboration with Aeris AS and SoftOx Solutions AS has created a new category for infection control products under the Aeris brand, which includes hand disinfectants from SoftOx Solutions. These three companies will now together market and sell Aeris's products to the pharmacies and the retail market in the Nordic countries and the UK.공시 • Dec 18+ 1 more updateUniversity of Copenhagen and SoftOx Solutions Reports on Positive Results on SoftOx Inhalation SolutionUniversity of Copenhagen and SoftOx Solutions reports on positive results on SoftOx Inhalation Solution (SIS). SoftOx Inhalation Solution (SIS) is an inhalation solution where the hypothesis is that it should be able to treat all types of respiratory tract infections. This could potentially be a paradigm shift in the treatment of all types of respiratory infections.공시 • Dec 13+ 4 more updatesSoftOx Solutions AS to Report Q4, 2020 Results on Mar 31, 2021SoftOx Solutions AS announced that they will report Q4, 2020 results on Mar 31, 2021Is New 90 Day High Low • Sep 28New 90-day high: kr81.00The company is up 9.0% from its price of kr74.50 on 30 June 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.공시 • Sep 26+ 1 more updateSoftOx Solutions AS Receives the Results of the Inhalation Studies in MinipigsSoftOx Solutions AS received the results of the inhalation studies in minipigs, which show very promising results with the intention to further develop the company's technology into a treatment of respiratory infections, including Covid19 patients. The results indicate that the company has found safe concentrations that do not damage the airways and at the same time show an antimicrobial effect.매출 및 비용 세부 내역SoftOx Solutions가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OB:SOFTX 매출, 비용 및 순이익 (NOK Millions)날짜매출순이익일반관리비연구개발비31 Dec 2516-116030 Sep 2514-36030 Jun 2511-156031 Mar 259-205031 Dec 248-435030 Sep 242-735030 Jun 242-615031 Mar 24-1-584031 Dec 237-398030 Sep 2314-1714030 Jun 2315-3420031 Mar 2316-5024031 Dec 227-7126030 Sep 227-6825030 Jun 226-6624031 Mar 227-6722031 Dec 218-6521030 Sep 216-7423030 Jun 216-6422031 Mar 2110-5321031 Dec 2010-3719030 Sep 209-3014030 Jun 209-2413031 Mar 204-1912031 Dec 194-1611030 Sep 195-1712030 Jun 197-1312031 Mar 196-1310031 Dec 184-139030 Sep 183-107030 Jun 180-125031 Mar 180-115031 Dec 170-94031 Dec 160-630양질의 수익: SOFTX 은(는) 현재 수익성이 없습니다.이익 마진 증가: SOFTX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: SOFTX는 수익성이 없지만 지난 5년 동안 연평균 19.2%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 SOFTX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: SOFTX은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(15.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: SOFTX는 현재 수익성이 없으므로 자본 수익률이 음수(-47.11%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 13:05종가2026/06/09 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SoftOx Solutions AS는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 27+ 1 more updateSoftOx Solutions AS to Report Fiscal Year 2025 Results on May 27, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on May 27, 2026
공시 • Dec 18+ 4 more updatesSoftOx Solutions AS to Report Fiscal Year 2025 Results on Jun 10, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on Jun 10, 2026
공시 • Jan 25+ 5 more updatesSoftOx Solutions AS to Report Fiscal Year 2024 Final Results on Jun 18, 2025SoftOx Solutions AS announced that they will report fiscal year 2024 final results on Jun 18, 2025
공시 • Dec 13+ 4 more updatesSoftOx Solutions AS to Report Q4, 2020 Results on Mar 31, 2021SoftOx Solutions AS announced that they will report Q4, 2020 results on Mar 31, 2021
공시 • 6hSoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments LimitedSoftOx Solutions AS has announced to issue 46 380 523 shares at an issue price of NOK 0.13 per share for gross proceeds of NOK 6,029,467.99 on June 9, 2026. The transaction includes returning investor participation from Long State Investments Limited.
공시 • Jun 05SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical StudySoftOx Solutions AS announced that the first participant has been enrolled in the SIS-02 Phase 1 clinical study in Ireland. The enrollment follows the previously announced approval of the SIS-02 clinical trial application by Ireland’s Health Products Regulatory Authority (HPRA) and marks the formal initiation of the study. The SIS-02 Phase 1 study is designed to evaluate the safety, tolerability, and pulmonary exposure profile of SoftOx Inhalation Solution (“SIS”) following inhaled administration in healthy volunteers and supports the continued development of SIS for defence and biological countermeasure applications. The initiation of SIS-2 represents an important operational milestone for SoftOx and expands the Company’s clinical trial pipeline from one to two ongoing clinical studies. SIS-02 is separate from, and independent of, the Company’s SIS-03 study in chronic lung infections in patients, including cystic fibrosis. Together, the two SIS programs support SoftOx’s strategy to develop SIS as an inhaled anti-infective therapy with potential relevance in both civilian healthcare and defence-related biological preparedness. The SIS-02 program is formally conducted through SoftOx’s wholly owned subsidiary, SoftOx Defense Solutions AS, and is grant-funded through SoftOx’s participation in the COUNTERACT Consortium, which is funded by the European Defence Fund and includes universities, public research institutes, and companies across Europe. The program is also supported by the Norwegian Ministry of Defence. The SIS-02 study is intended to add to the clinical evidence base for SIS and support the planning of subsequent development activities. SoftOx will provide further updates on SIS-02 as the study progresses and when relevant data reviews have been completed. SoftOx Solutions AS is developing SIS, a novel inhaled anti-infective therapy for respiratory infections in the airways and lungs. Delivered by nebulizer, SIS is being developed to address bacterial, viral, and fungal pathogens through local delivery directly at the site of infection, without systemic exposure to the remainder of the human body. Its broad pathogen relevance positions SIS as a distinct therapeutic in respiratory infections.
분석 기사 • Mar 28We Think SoftOx Solutions (OB:SOFTX) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Mar 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Revenue is less than US$5m (kr16m revenue, or US$1.6m). Market cap is less than US$100m (kr174.4m market cap, or US$18.1m).
New Risk • Dec 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr219.9m market cap, or US$21.9m).
공시 • Dec 19+ 5 more updatesSoftOx Solutions AS, Annual General Meeting, Jun 23, 2027SoftOx Solutions AS, Annual General Meeting, Jun 23, 2027.
공시 • Sep 27SoftOx Solutions AS announced that it has received NOK 6 million in funding from Long State Investments LimitedOn September 26, 2025, SoftOx Solutions AS closed the transaction.
공시 • Jun 30SoftOx Solutions AS Appoints Tore Duvold as New Board MemberSoftOx Solutions AS at its Annual General Meeting, announced the election of Dr. Tore Duvold as a new member of the Board of Directors. Dr. Duvold brings over 25 years of experience in the life science sector, including leadership roles in biotech, pharma, and public innovation funding. He currently serves as CEO of the Swedish diagnostics company Spermosens AB and has held senior positions at LEO Pharma, Aker Biopharma AS, Innovation Fund Denmark, Edvince AB, and Coegin Pharma. In addition, he has served on the board of Medicon Valley Alliance and been involved in several board roles.
공시 • May 27+ 1 more updateSoftOx Solutions AS to Report Fiscal Year 2025 Results on May 27, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on May 27, 2026
공시 • Dec 19SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026SoftOx Solutions AS, Annual General Meeting, Jun 24, 2026.
공시 • Dec 18+ 4 more updatesSoftOx Solutions AS to Report Fiscal Year 2025 Results on Jun 10, 2026SoftOx Solutions AS announced that they will report fiscal year 2025 results on Jun 10, 2026
공시 • Sep 13SoftOx Solutions AS to Appeal Court Ruling in Consultant Bonus DisputeThe District Court of Ringerike, Asker, and Bærum has made its ruling in a dispute between SoftOx Solutions AS and a former consultant claiming to have a bonus claim for services rendered in 2022. The district court ruled in favor of the consultant and awarded the consultant approx. NOK 2.5 million plus interest, and NOK 484,000 in compensation including legal costs. The Company believes that the claim has no merits, and the ruling will be appealed.
공시 • Sep 12SoftOx Solutions AS Elects Additional Board MembersSoftOx Solutions AS at its ExtraOrdinary General Meeting held on 12 September 2024, elected as additional board member: Christian Vinding Thomsen, Vice Chairman of the Board and Eskil Zapffe, board member with an election term until the annual general meeting in 2025.
공시 • Jul 03+ 1 more updateSoftox Solutions as Announces CFO ChangesSoftOx Solutions AS announced that in this process the former CFO Harald Sætvedt has stepped down and will be replaced by CFO Ingrid Juven. Ingrid Juven has over 25+ years of consulting and management expertise within a variety of industries. Juven holds an MBA from BI Norwegian Business School.
공시 • May 01SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million.SoftOx Solutions AS has completed a Follow-on Equity Offering in the amount of NOK 2.66919 million. Security Name: Shares Security Type: Common Stock Securities Offered: 13,345,951 Price\Range: NOK 0.2 Transaction Features: Rights Offering
New Risk • Apr 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 47x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 47x increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$645k). Minor Risks Negative equity (-kr268k). Market cap is less than US$100m (kr156.1m market cap, or US$14.4m).
New Risk • Apr 05New minor risk - Negative shareholders equityThe company has negative equity. Total equity: -kr268k This is considered a minor risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. It should be noted that some of the negative equity could be due to large buybacks of stock, which is not as much of a risk as a company with overwhelming debt, but likewise is not sustainable in the long-term. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$650k). Market cap is less than US$10m (kr4.29m market cap, or US$399.5k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).
공시 • Mar 28SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million.SoftOx Solutions AS has filed a Follow-on Equity Offering in the amount of NOK 25 million. Security Name: Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: NOK 0.2 Transaction Features: Rights Offering
New Risk • Mar 27New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.0m (US$649k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m (kr7.0m revenue, or US$649k). Market cap is less than US$10m (kr8.84m market cap, or US$821.8k). Minor Risks Negative equity (-kr268k). Shareholders have been diluted in the past year (3.7% increase in shares outstanding).
공시 • Jan 25+ 5 more updatesSoftOx Solutions AS to Report Fiscal Year 2024 Final Results on Jun 18, 2025SoftOx Solutions AS announced that they will report fiscal year 2024 final results on Jun 18, 2025
New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (kr51.7m market cap, or US$4.79m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).
Board Change • Mar 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Kari Myren was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Dec 30+ 4 more updatesSoftOx Solutions AS, Annual General Meeting, Mar 28, 2024SoftOx Solutions AS, Annual General Meeting, Mar 28, 2024.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman Melvin Teigen was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Sep 01Is SoftOx Solutions (OB:SOFTX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
공시 • Mar 17Danish Medicines Agency Approves First-In-Human Clinical Study for SoftOx Solutions AS Wound Treatment Agent for Infections in Chronic Wounds, Biofilm EradicatorSoftOx Solutions AS announced that the Danish Medicines Agency (DKMA) has authorised the SBE-01 clinical trial on medicinal products. The authorisation is given pursuant to § 88(1) of the Danish Medicines Act.1. This is the first-in-man (phase I) study with lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. This approval represents an important milestone for SoftOx Solutions AS and is of crucial importance for the further development of an effective infection treatment of problematic wounds, where there is an unmet medical need. It is also an important step forward for the company's collaboration and funding partners, such as University of Copenhagen, Bispebjerg University Hospital, US Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) and The Research Council of Norway. The SBE-01 study will commence as soon as permission has also been granted by the relevant Scientific Ethical Committee. SBE-01: EudraCT no. 2021-000314-42.
Is New 90 Day High Low • Feb 20New 90-day low: kr56.50The company is down 18% from its price of kr68.50 on 20 November 2020. The Norwegian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
분석 기사 • Feb 19How Many SoftOx Solutions AS (OB:SOFTX) Shares Have Insiders Sold, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
분석 기사 • Jan 15SoftOx Solutions (OB:SOFTX) Will Have To Spend Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. Indeed, SoftOx Solutions...
공시 • Dec 23SoftOx Solutions AS Announces New Distribution AgreementSoftOx Solutions AS announced new distribution agreement. Distributor Bonaventura Scandza has signed an agreement with NorgesGruppen for the sale of SafeDes alcohol-free hand disinfectant. From February, some of the country's grocery chains will start selling SoftOx SafeDes hand disinfectant under the brand name «Aeris». The agreement with NorgesGruppen includes Meny, Spar, and Bunnpris stores, where 39 Meny stores will include the products in a fixed listing, while partner Bonaventura Scandza will be allowed to sell products to all the other stores locally. Meny has a total of 200 stores, Spar has 295, and Bunnpris has 250. As a result of increased focus on infection prevention and control among consumers, Bonaventura Scandza in collaboration with Aeris AS and SoftOx Solutions AS has created a new category for infection control products under the Aeris brand, which includes hand disinfectants from SoftOx Solutions. These three companies will now together market and sell Aeris's products to the pharmacies and the retail market in the Nordic countries and the UK.
공시 • Dec 18+ 1 more updateUniversity of Copenhagen and SoftOx Solutions Reports on Positive Results on SoftOx Inhalation SolutionUniversity of Copenhagen and SoftOx Solutions reports on positive results on SoftOx Inhalation Solution (SIS). SoftOx Inhalation Solution (SIS) is an inhalation solution where the hypothesis is that it should be able to treat all types of respiratory tract infections. This could potentially be a paradigm shift in the treatment of all types of respiratory infections.
공시 • Dec 13+ 4 more updatesSoftOx Solutions AS to Report Q4, 2020 Results on Mar 31, 2021SoftOx Solutions AS announced that they will report Q4, 2020 results on Mar 31, 2021
Is New 90 Day High Low • Sep 28New 90-day high: kr81.00The company is up 9.0% from its price of kr74.50 on 30 June 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
공시 • Sep 26+ 1 more updateSoftOx Solutions AS Receives the Results of the Inhalation Studies in MinipigsSoftOx Solutions AS received the results of the inhalation studies in minipigs, which show very promising results with the intention to further develop the company's technology into a treatment of respiratory infections, including Covid19 patients. The results indicate that the company has found safe concentrations that do not damage the airways and at the same time show an antimicrobial effect.